期刊
MACROMOLECULAR BIOSCIENCE
卷 17, 期 4, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/mabi.201600343
关键词
combination therapy; doxorubicin; multidrug-resistant ancer cells; multivalent aptamers; siRNA
资金
- Global Innovative Research Center (GiRC) program through National Research Foundation (NRF) - Ministry of Education, Science and Technology, Republic of Korea [NRF-2012K1A1A2A01056094]
- Ministry of Science & ICT (MSIT), Republic of Korea [2E26923] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
- National Research Foundation of Korea [2012K1A1A2A01056094] Funding Source: Korea Institute of Science & Technology Information (KISTI), National Science & Technology Information Service (NTIS)
Multivalent aptamer-siRNA conjugates containing multiple mucin-1 aptamers and BCL2specific siRNA are synthesized, and doxorubicin, an anthracycline anticancer drug, is loaded into these conjugates through intercalation with nucleic acids. These doxorubicin-incorporated multivalent aptamer-siRNA conjugates are transfected to mucin-1 overexpressing MCF-7 breast cancer cells and their multidrug-resistant cell lines. Doxorubicin-incorporated multivalent aptamer-siRNA conjugates exert promising anticancer effects, such as activation of caspase-3/7 and decrease of cell viability, on multidrug-resistant cancer cells because of their high intracellular uptake efficiency. Thus, this delivery system is an efficient tool for combination oncotherapy with chemotherapeutics and nucleic acid drugs to overcome multidrug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据